TNF inhibitor

      1yr results using anti-IL-23 Guselkumab shows the same ACR 20/50/70 responses regardless of prior TNF inhibitor failure.

      Dr. John Cush RheumNow

      4 years 5 months ago

      1yr results using anti-IL-23 Guselkumab shows the same ACR 20/50/70 responses regardless of prior TNF inhibitor failure. #ACR20 #Abstr#1344 https://t.co/OvgJ53wwmU https://t.co/JdajDONWap

      meeting.photo_.jpg
      ACR20 - Day 2 Report
      4 years 5 months ago
      Saturday was the day 2 with many posters and live sessions at the 2020 Virtual ACR/ARP meeting. Here are a few of my highlights from day two: Targeting Plasmacytoid Dendritic Cells in Lupus…
      RT @philipcrobinson: For all your nr-axSpA fanatics, there's a fantastic poster on certolizumab response in nr-axSpA str

      Dr Philip Robinson philipcrobinson

      4 years 5 months ago
      For all your nr-axSpA fanatics, there's a fantastic poster on certolizumab response in nr-axSpA stratified by MRI and CRP status #ACR20 @steverheum_hall https://t.co/WI1vdMItUO https://t.co/JnvAyyClDu
      RT @drpnash: Time to Discontinuation of Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients with and Without

      Peter Nash drpnash

      4 years 5 months ago
      Time to Discontinuation of Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients with and Without Methotrexate: Real World Results from a Rheumatoid Arthritis Cohort https://t.co/ZzhE0J7dOX #TOFA #TNFi TNFi does better with MTX Tofa less necessary
      RT @synovialjoints: Etanercept monotherapy significantly more effective than Methotrexate monotherapy in maintaining rem

      Dr. Antoni Chan synovialjoints

      4 years 5 months ago

      Etanercept monotherapy significantly more effective than Methotrexate monotherapy in maintaining remission in RA patients on combination therapy. Data from the SEAM-RA study @RheumNow #ACR20 Abstr#0939 #ACRbest

      RT @RichardPAConway: After the SEAM-RA study, in patients taking MTX and ETN in sustained remission would you? #ACR20 @r

      Richard Conway RichardPAConway

      4 years 5 months ago

      After the SEAM-RA study, in patients taking MTX and ETN in sustained remission would you? #ACR20 @rheumnow

      RT @KDAO2011: We have great options all around! Both are efficacious in biologic (TNFi) failures for RA patients.

      Compa

      k dao KDAO2011

      4 years 5 months ago
      We have great options all around! Both are efficacious in biologic (TNFi) failures for RA patients. Comparative Clinical Efficacy of Sarilumab versus Upadacitinib over 12 Weeks: Matching-Adjusted Indirect Comparison Analysis Abst#0827 #ACR20 @RheumNow https://t.co/1SsL9qLJD3
      RT @ejdein1: SEAM-RA trial Abst#0939 Combo TNF/MTX Rx -> ETN monoRx superior to MTX monoRx in sustaining remisson, si

      Eric Dein ejdein1

      4 years 5 months ago

      SEAM-RA trial Abst#0939 Combo TNF/MTX Rx -> ETN monoRx superior to MTX monoRx in sustaining remisson, simliar to staying on combo Rx. #ACR20 @RheumNow. Benefit of continuing combo: protect HACA Ab and longevity of TNFi https://t.co/Q934naKnBq

      RT @Janetbirdope: Another biosimilar Adalimumab. SB5 switch in RA, PsA & SpA N=354 No diff in effectiveness Some min

      Janet Pope Janetbirdope

      4 years 5 months ago

      Another biosimilar Adalimumab. SB5 switch in RA, PsA & SpA N=354 No diff in effectiveness Some minor flares. Some changed dose unsure why. #ACR2020 @RheumNow @CRASCRRheum abstr#805 https://t.co/2Zb4H2jBXQ

      RT @uptoTate: MEASURE2 and COAST-W data stratified by TNFi inadequate responders may suggest different axSpA subset (dom

      Dr. Rachel Tate uptoTate

      4 years 5 months ago
      MEASURE2 and COAST-W data stratified by TNFi inadequate responders may suggest different axSpA subset (domain?) response to TNFi vs IL17i. Dr. J. Ermann #ACR20 @RheumNow #ACRbest https://t.co/0ZcEIvkuMj

      Podcasts

      • EMR Messaging Woes (4.11.2025)
      • An Epidural Letdown (4.4.2025)
      • Biomarkers in RA

      Catch up on Conference Podcasts

      ×